Michael R. Ujhelyi;Xiaohong Zhou;Daniel C. Sigg;Keith R. Hildebrand;Linda M. Page
发明人:
Keith R. Hildebrand,Michael R. Ujhelyi,Xiaohong Zhou,Daniel C. Sigg,Linda M. Page
申请号：
US12128046
公开号：
US08348884B2
申请日:
2008.05.28
申请国别(地区):
US
年份:
2013
代理人:
摘要：
A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine).
